PCI Pharma Services secured new investments from Bain Capital, Kolberg, and Mubadala, valuing the contract development and manufacturing organization (CDMO) at approximately $10 billion. The funds will drive geographic growth, enhanced fill-finish capabilities, and drug production for specialized modalities including PROTACs and antibody-drug conjugates. With 30 facilities worldwide and a recent San Diego acquisition, PCI aims to strengthen U.S. drug manufacturing. CEO Salim Haffar emphasizes a strategic transformation into a global CDMO to meet accelerating industry demand.